Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMANASDAQ:AKRONASDAQ:BGMNASDAQ:PCVX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$21.60-1.2%$20.81$10.21▼$25.67$5.16B0.473.67 million shs3.63 million shsAKROAkero Therapeutics$53.56+1.1%$43.18$21.02▼$58.40$4.27B-0.161.00 million shs1.57 million shsBGMQilian International Holding Group$15.61-4.5%$12.05$5.26▼$17.17$1.52B1.3829,690 shs115,593 shsPCVXVaxcyte$34.46-2.8%$32.54$27.66▼$121.06$4.45B1.21.44 million shs1.21 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics+4.84%+7.58%+6.94%+22.11%+108.29%AKROAkero Therapeutics-2.86%-0.06%+27.52%+18.06%+126.03%BGMQilian International Holding Group-0.06%+26.84%+43.23%+65.65%+1,634,999,900.00%PCVXVaxcyte-4.73%+4.73%+12.19%-51.47%-51.17%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMAADMA Biologics2.1858 of 5 stars2.61.00.00.02.12.51.9AKROAkero Therapeutics3.7974 of 5 stars3.51.00.04.72.81.70.0BGMQilian International Holding GroupN/AN/AN/AN/AN/AN/AN/AN/APCVXVaxcyte2.8202 of 5 stars4.62.00.00.02.11.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 3.25Buy$24.2512.27% UpsideAKROAkero Therapeutics 3.00Buy$82.5054.03% UpsideBGMQilian International Holding Group 0.00N/AN/AN/APCVXVaxcyte 3.10Buy$136.50296.11% UpsideCurrent Analyst Ratings BreakdownLatest BGM, ADMA, PCVX, and AKRO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025AKROAkero TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$63.00 ➝ $64.005/13/2025AKROAkero TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$80.00 ➝ $78.005/8/2025ADMAADMA BiologicsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$25.00 ➝ $32.004/22/2025PCVXVaxcyteCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight4/8/2025PCVXVaxcyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$90.00 ➝ $90.004/1/2025PCVXVaxcyteThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$138.00 ➝ $100.004/1/2025PCVXVaxcyteBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$157.00 ➝ $137.004/1/2025PCVXVaxcyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$140.00 ➝ $90.003/31/2025PCVXVaxcyteEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/12/2025PCVXVaxcyteGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$160.00 ➝ $160.00(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$459.38M11.23$0.07 per share311.70$0.60 per share36.00AKROAkero TherapeuticsN/AN/AN/AN/A$9.61 per shareN/ABGMQilian International Holding Group$25.10M60.47N/AN/A$6.10 per share2.56PCVXVaxcyteN/AN/AN/AN/A$13.04 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics-$28.24M$0.8577.1431.30N/A17.80%53.20%26.07%8/6/2025 (Estimated)AKROAkero Therapeutics-$151.76M-$1.95N/AN/AN/AN/A-32.46%-29.83%8/8/2025 (Estimated)BGMQilian International Holding Group-$1.44MN/A0.00∞N/AN/AN/AN/AN/APCVXVaxcyte-$402.27M-$3.99N/AN/AN/AN/A-23.53%-22.20%8/5/2025 (Estimated)Latest BGM, ADMA, PCVX, and AKRO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025PCVXVaxcyte-$1.02-$1.04-$0.02-$1.04N/AN/A5/12/2025Q1 2025AKROAkero Therapeutics-$1.01$0.90+$1.91$0.90N/AN/A5/7/2025Q1 2025ADMAADMA Biologics$0.16$0.14-$0.02$0.11$116.40 million$114.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AAKROAkero TherapeuticsN/AN/AN/AN/AN/ABGMQilian International Holding GroupN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.487.093.26AKROAkero Therapeutics0.0517.2517.25BGMQilian International Holding GroupN/A3.392.82PCVXVaxcyteN/A17.8817.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%AKROAkero TherapeuticsN/ABGMQilian International Holding GroupN/APCVXVaxcyte96.78%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.50%AKROAkero Therapeutics7.07%BGMQilian International Holding Group58.66%PCVXVaxcyte3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530238.73 million227.64 millionOptionableAKROAkero Therapeutics3079.72 million64.26 millionOptionableBGMQilian International Holding Group29897.22 million2.48 millionN/APCVXVaxcyte160129.00 million120.77 millionOptionableBGM, ADMA, PCVX, and AKRO HeadlinesRecent News About These CompaniesVaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Rhumbline AdvisersJune 12 at 3:40 AM | marketbeat.comCantor Fitzgerald Forecasts Vaxcyte FY2026 EarningsJune 12 at 1:45 AM | americanbankingnews.comBrokers Offer Predictions for Vaxcyte FY2026 EarningsJune 11 at 8:45 AM | marketbeat.comVaxcyte: Sentiment Is Pushing The Shares DownJune 10 at 1:57 PM | seekingalpha.comBrokerages Set Vaxcyte, Inc. (NASDAQ:PCVX) PT at $136.50June 8, 2025 | americanbankingnews.comVaxcyte (NASDAQ:PCVX) vs. Neumora Therapeutics (NASDAQ:NMRA) Critical ReviewJune 5, 2025 | americanbankingnews.comVaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of "Buy" by AnalystsJune 5, 2025 | marketbeat.com103,683 Shares in Vaxcyte, Inc. (NASDAQ:PCVX) Purchased by Universal Beteiligungs und Servicegesellschaft mbHJune 1, 2025 | marketbeat.comCalifornia State Teachers Retirement System Has $8.60 Million Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)June 1, 2025 | marketbeat.comVaxcyte (NASDAQ:PCVX) Stock Price Up 5.7% - Should You Buy?May 30, 2025 | marketbeat.comHere’s Why Vaxcyte (PCVX) Sold Off in Q1May 27, 2025 | msn.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)May 27, 2025 | marketbeat.comToronto Dominion Bank Invests $900,000 in Vaxcyte, Inc. (NASDAQ:PCVX)May 26, 2025 | marketbeat.comFrazier Life Sciences Management L.P. Trims Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)May 23, 2025 | marketbeat.comMillennium Management LLC Sells 21,857 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)May 23, 2025 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) is Windsor Advisory Group LLC's 4th Largest PositionMay 22, 2025 | marketbeat.comWoodline Partners LP Increases Stake in Vaxcyte, Inc. (NASDAQ:PCVX)May 22, 2025 | marketbeat.comProShare Advisors LLC Purchases 11,729 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)May 22, 2025 | marketbeat.comNuveen Asset Management LLC Acquires 65,713 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)May 22, 2025 | marketbeat.comSoleus Capital Management L.P. Buys 72,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)May 21, 2025 | marketbeat.com279,944 Shares in Vaxcyte, Inc. (NASDAQ:PCVX) Purchased by Twinbeech Capital LPMay 21, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBGM, ADMA, PCVX, and AKRO Company DescriptionsADMA Biologics NASDAQ:ADMA$21.60 -0.27 (-1.23%) As of 04:00 PM EasternADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Akero Therapeutics NASDAQ:AKRO$53.56 +0.60 (+1.13%) As of 04:00 PM EasternAkero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Qilian International Holding Group NASDAQ:BGM$15.61 -0.74 (-4.53%) As of 04:00 PM EasternQilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.Vaxcyte NASDAQ:PCVX$34.46 -0.98 (-2.77%) As of 04:00 PM EasternVaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ignore the Noise—Samsara Stock Is Still a Strong Buy Oracle’s Cloud Boom Is Just Getting Started Netflix Sets New Highs—Price Targets Keep Climbing IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA Alibaba’s Dip Is a Gift—Here’s the Price That Matters Betting on Disruption: Is Lemonade the Future of Insurance? Starbucks Stock: Culture Fix May Be Key to Long-Term Growth GameStop Turns a Profit, But Core Business Keeps Shrinking Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
